Institutional Titan Hits the Jackpot: Biotech Stock Surges by 116% on Buyout Offer

On November 14, 2025, Bain Capital Life Sciences Investors, LLC disclosed a purchase of 520,310 shares of Cidara Therapeutics (NASDAQ:CDTX), increasing its position value by approximately $167.48 million.Bain Capital Life Sciences Investors, LLC reported in a November 14, 2025, SEC filing that it increased its stake in Cidara Therapeutics by 520,310 shares during the third quarter. The position’s value rose to $289.29 million, up from the previous period. The transaction contributed an estimated $167.48 million in value change, factoring in both share purchases and price appreciation.This buy brought the CDTX stake to 19.2% of the fund’s 13F reportable assets under management, making it the 3rd-largest holding.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool